Monkeypox Vaccine and Treatment Market Size, Share, By Product Type (Vaccine (JYNNEOS/ Imvanex, Smallpox Vaccine, Others), Drugs (Tecovirimat, Brincidofovir, Cidofovir, Others), and Vaccinia Immune Globulin), By Gender Type (Male, Female, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others (Government agencies)), and By Region - Trends, Analysis and Forecast till 2034

Monkeypox Vaccine and Treatment Market Size was valued at USD 85.4 Billion in 2024 and is expected to reach USD 215.7 Billion by 2034, growing at a CAGR of 10.7%

After the outbreak in 2022, the demand surged for the Monkeypox Vaccine market, thus preparing against emerging infectious diseases and rapid expansion. This earlier small market now focuses on shielding vulnerable populations from the virus. The key players include pharmaceutical companies, government agencies, and research institutions. High competition characterizes the market, where efficacy, safety, and price are critical factors. As a result of this surge in demand, there is pressure on global supplies: more production capacity and, notably, its more equitable distribution. Given this, the monkeypox vaccine market's future is likely to be uncertain, dependent on the efficacy of public health measures, new vaccine development, and virus variants.